

DNA REPAIR GENES AND THEIR ROLE IN LUNG CANCER DEVELOPMENT

E. Halasova¹, M. Franeckova¹, T. Matakova², M. Halasa³, T. Dzian⁴, S. Javorkova⁵, K. Javorka⁶, L. Musak⁷

¹Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Department of Medical Biology, Malá Hora 4, 036 01 Martin, Slovak Republic, halasova@jfmed.uniba.sk

²Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Department of Medical Biochemistry, Malá Hora 4, 036 01 Martin, Slovak Republic

³University Hospital Martin, Clinic of Surgery and Transplantation Centre, Kollárova 2, 036 01 Martin, Slovak Republic

⁴University Hospital Martin, Clinic of Thoracic Surgery, Kollárova 2, 036 01 Martin, Slovak Republic

⁵Central Military Hospital Ružomberok, Clinic of Paediatrics, Slovak Republic Generála Miloša Vesela 21, 03426 Ružomberok

⁶The Catholic University in Ružomberok, Faculty of Health Care, The Department of Midwifery, Námestie A. Hlinku 48, 034 01 Ružomberok

⁷Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Clinic of Occupational Medicine and Toxicology, Mala Hora 4, 036 01 Martin, and University Hospital Martin, Kollárova 2, 036 01 Martin, Slovak Republic

Objective: Gene polymorphisms of DNA repair genes are associated with the risk of developing sporadic and hereditary tumours. In the present case-control study, we investigated gene polymorphisms of selected DNA repair genes and their risk for lung cancer development in Slovak population.

Material and methods: The study includes 422 lung cancer patients and 511 healthy individuals. Single gene polymorphisms of *hMLH1*, *hMSH2*, *XRCC1*, *XRCC3*, *XPB* and *XPC* were analysed. Statistical analysis was carried out using SNP & Variation Suite v7.6.11 software.

Results: Risk of lung cancer development was significantly decreased for *XPC* Gln/Gln genotype (OR = 0,59, 95 % CI = 0,34 - 1,02, p = 0,04) and significantly increased for *hMSH2*, variant (CC) genotype (OR=2,27; 95%CI=1, 12-4, 63; P=0,024).

Observing gene combinations, increased risk was found for following genotypes: *XPB* Lys/Gln + *XPC* Lys/Lys (OR = 1,87, p = 0,03), *XRCC1* Arg/Gln + *XPC* Lys/Lys (OR = 4,52, p = 0,0007), *XRCC1* Arg/Gln + *XPC* Lys/Gln (OR = 5,44, p = < 0,0001) in men and *XRCC1* Arg/Arg + *hOGG1* Ser/Cys (OR = 2,64, p = 0,04), *XRCC1* Arg/Gln + *hOGG1* Ser/Ser (OR = 3,05, p = 0,003), *XRCC1* Arg/Gln + *hOGG1* Cys/Cys (OR = 5,45, p = 0,04), *XRCC1* Gln/Gln + *hOGG1* Ser/Ser (OR = 6,81, p = 0,0013), *XRCC1* Arg/Gln + *XPC* Lys/Gln (OR = 3,18, p = 0,02), *XRCC1* Arg/Gln + *XPC* Gln/Gln (OR = 3,85, p = 0,03), *XRCC1* Arg/Gln + *XPB* Lys/Lys (OR = 2,78, p = 0,02), *XRCC1* Gln/Gln + *XPB* Lys/Lys (OR = 4,08, p = 0,03) in women.

Conclusions: We conclude that polymorphisms of DNA repair genes underscore the risk of lung cancer development.

Acknowledgements: This work was supported by Grant APVV-0412-11 and by the Ministry of Health of Slovak Republic Grant No. 2012/25-UKMA-2.

Key words: single nucleotide polymorphism, *hMLH1*, *hMSH2*, *XRCC1*, *XRCC3*, *XPB*, *XPC*, lung cancer risk

